Does early immunotherapy reduce the conversion of ocular myasthenia gravis to generalized myasthenia gravis?

M. Kupersmith

DOI: https://doi.org/10.1097/00041327-200312000-00001

2003-12-01

Journal of Neuro-Ophthalmology

Abstract:Background: Several retrospective studies have suggested that immunotherapy, including prednisolone, azathioprine and thymectomy, reduces progression of ocular myasthenia gravis to generalized myasthenia gravis. This study examines the effect of immunotherapy on generalization rates in ocular myasthenia patients who are acetylcholine receptor (AChR) antibody-positive. Methods: Retrospective record review of 34 patients from three university-based hospitals with neurology and neuroophthalmology services in Australia. In all patients, positive AChR antibodies were recorded, the initial symptoms were purely ocular, and all had at least 2 years of follow-up. The patients who developed generalized myasthenia gravis were compared with those who remained purely ocular. Results: There were 21 patients who developed generalized myasthenia gravis. Of these 21, only 2 (9.5%) had received prior immunotherapy. Among the 13 patients whose symptoms remained purely ocular, 10 (76.9%) had received prior immunotherapy. Conclusions: In this study, most of the patients who progressed from ocular myasthenia to generalized myasthenia had not received prior immunotherapy. This study adds weight to the call for a prospective trial of early immunotherapy in patients with ocular myasthenia. (JNeuro-Ophthalmol 2003;23: 251-255) yasthenia gravis is an autoimmune condition in which antibodies to the acetylcholine receptor (AChR) cause weakness of somatic musculature. In ocular myasthenia, the weakness is limited to the extraocular, levator, and orbicularis oculi muscles. Progression to generalized myasthenia occurs in about 50%>, usually within 2 From the Royal Victorian Eye and Ear Hospital (JM, MP, JK, JO), and St Vincent's Hospital (MP, EB, KR), Melbourne, Australia Address correspondence to Justin O'Day, MB BS, FRANZCO, Level 1, 55 Victoria Pde, Fitzroy, Melbourne, Australia, 3065; E-mail: JustinODay@bigpond.com or 3 years (1,2). Ocular myasthenia is treated according to symptoms with pyridostigmine and immunotherapies such as prednisolone, azathioprine, and thymectomy. Prednisolone and azathioprine doses are minimized to limit side effects. Thymectomy is used to treat younger patients with thymic enlargement noted on computed tomography (CT). Studies by Sommer et al (3) and Kupersmith et al (4) suggest that immunotherapy may reduce the risk of generalization in ocular myasthenia. Studies of ocular myasthenia can, however, be compromised by vague diagnostic criteria in seronegative patients, inadequate follow-up times, or selection bias from the inclusion of patients presenting with many years of purely ocular symptoms. In this study, we reviewed 34 AchR-positive patients to find the effect of immunotherapy on generalization. METHODS Patients were identified from a central database of AChR antibody tests. Ethical approval was obtained from all three involved hospitals to access the AChR database and to view medical records with consent from the patient. All patients had been examined by neurologists or neuroophthalmologists between January 1990 and January 2002. Most patients had presented between 1998 and 2002. Using the AChR database and medical records, we found 44 patients who were AchR-positive on first or subsequent testing and whose initial symptoms were purely ocular. We excluded four patients who had less than 2 years of follow-up from their initial symptoms, to reduce selection bias, three patients who had more than 2 years of ocular symptoms before their first presentation were also excluded. Three patients were excluded because it could not be determined whether they had received significant immunotherapy. One excluded patient had only 1 month of prednisolone and the other two patients had developed systemic myasthenia at 3 and 6 months post-thymectomy, given that this procedure generally takes 6 months to 3 years to have its effect. The treatment approach of different physicians varied slightly. The general approach was to treat first with an anticholinesterase and then introduce prednisolone 25mg Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. J Neuro-Ophthalmol, Vol. 23, No. 4, 2003 251 JNeuro-Ophthalmol, Vol. 23, No. 4, 2003 Mee et al daily if the symptoms were troublesome. If the prednisolone could not be tapered over the following months, then azathioprine might be prescribed. Videoscopic thymectomy was considered in patients with an enlarged thymus onCT. Generalization was determined from the patient records, based on the opinion of the treating neurologists or neuro-ophthalmologists. Antibodies to AChR were measured by radioimmunoassay according to the method of Vincent and NewsomDavis (5). The source of antigen was receptor protein from cell line TE671, a subline of the rhabdomyosarcoma cell line. TE671-sourced AChR receptors labeled with I Alpha bungarotoxin were incubated with patient specimens and then immunoprecipitated with anti-human IgG. After centrifugation, the labeled AChRautoantibody-bound complex was counted in a gamma counter.